Breaking News Instant updates and real-time market news.


Resverlogix says BETonMACE trial did not meet primary endpoint

Resverlogix announces that BETonMACE did not meet the primary endpoint - reduction in major adverse cardiovascular events, defined as cardiovascular death, non-fatal myocardial infarction and stroke - added to standard of care in high-risk patients with type 2 diabetes, recent acute coronary syndrome, and low HDL cholesterol. Apabetalone demonstrated tolerability and safety. Full study results will be presented during a late-breaking science session at AHA 2019. The primary results of the BETonMACE trial will be presented in the near future during the American Heart Association's Scientific Sessions 2019 held in Philadelphia, Pennsylvania, and submitted for peer review. The presentation is currently scheduled for approximately 11:42 am ET on November 16, 2019.


Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.